Processes in atherogenesis: Complement activation

Atherosclerosis

Volumn 132, Issue 2, 1997, Pages 131-138

  Torzewski, Jan ^a   Bowyer, David E ^b   Waltenberger, Johannes ^a   Fitzsimmons, Colin ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; C5b 9; Complement activation; Membrane attack complex

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; LOW DENSITY LIPOPROTEIN; REGULATOR PROTEIN;

ATHEROGENESIS; CELL ACTIVATION; COMPLEMENT ACTIVATION; CYTOLYSIS; FOAM CELL; HUMAN; HUMORAL IMMUNITY; LEUKOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0030793987     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00100-7     Document Type: Article

References (77)

1. Gardinali M, Conciato L, Cafaro C, Agostino A. Complement system in coronary heart disease: a review. Immunopharmacology 1995;30:105-17.
2. Smiley JD, Moore SE. Immnune complex vasculitis: role of complement and IgG Fc receptor functions. Am J Med Sci 1989;289:267-77.
3. Faulk WP, Labarrere CA, Pitts D, Halbrook H. Laboratory clinical correlates of time associated lesions in the vascular immunopathology of human cardiac allografts. J Heart Lung Transplant 1993;12:S125-34.
4. Seifert PS, Kazatchkine MD. The complement system in atherosclerosis. Atherosclerosis 1988;73:91-104.
5. Torzewski J, Oldroyd R, Lachmann PJ, Fitzsimmons CJ, Proudfoot D, Bowyer DE. Complement induced release of monocyte chemotactic protein from human smooth muscle cells a possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 1996;16:673-7.
6. Liszewsbi MK, Atkinson JP. In: Paul WE, editor. The Complement System in Fundamental Immunology, 3rd edn., 1993:917-939.
7. Hugli TE, Müller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978;26:1-53.
8. Morgan BP. Effects of the membrane attack complex on nucleated cells. Curr Top Microbiol Immunol 1992;178:115-40.
9. Shin HS, Snyderrnan R, Friedman E, Mellors A, Mayer MM. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 1968;162:361-3.
10. Goldstein IM, Weissmann G. Generation of C5 derived lysosomal enyme releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974;113:1583-7.
11. Johnson AR, Hugli TE, Müller-Eberhard HJ. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975;28:1067-71.
12. Schumacher WA, Fantone JC, Kunkel SE, Webb RC, Luccchesi BR. The anaphylatoxins C3a and C5a are vasodilatators in the canine coronary vasculature in vitro and in vivo. Agents Actions Suppl 1991;34:345-9.
13. Ember JA, Sanderson SD, Taylor SM, Kawahara M, Hugli TE. Biological activity of synthetic analogues of C5a anaphylatoxin. J Immunol 1992;148:3165-73.
14. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a induced expression of P selectin in endothelial cells. J Clin Invest 1994;94:1147-55.
15. Morgan BP. Complement: Clinical aspects and relevance to disease. London: Academic Press, 1990:1-49.
16. Bhakdi S, Hugo F, Tranum-Jensen J. Functions and relevance of the terminal complement sequence. Blut 1990;60:309-18.
17. Cybulski A, Cyr M. Phosphatidyl choline directed phospholipase C: activation by complement C5b-9. Am J Physiol 1993;265:551-6.
18. Haensch GM, Torbohm I, Rother K. Chronic glomerulonephritis: inflamammatary mediators stimulate collagen synthesis in glomerular epithelial cells. Int Arch Allergy Appl Immunol 1989;88:139-43.
19. Lachmann PJ. The control of homologous lysis. Immunol Today 1991;12:312-5.
20. Stary HC. The histological classification of atherosclerotic lesions in human coronary arteries. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott Raven Publishers, 1996:463-474.
21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
22. Davies DF. Hypothesis: An immunological view of atherogenesis. J Atheroscler Res 1969;10:253-9.
23. Poston RN, Davies DF. Immunity and inflammation in the pathogenesis of atherosclerosis. Atherosclerosis 1974;19:253-7.
24. Minick RC, Murphy GE, Campbell JR. Experimental induction of atherosclerosis by the synergy of allergic injury to arteries and lipid rich diet. J Exp Med 1966;12:635-40.
25. Howard AN, Patelski J, Bowyer DE, Gresham GA. Atherosclerosis induced in hypercholesterolemic baboons by immunological injury and the effects of intravenous polyunsaturated phosphatidyl choline. Atherosclerosis 1971;14:17-21.
26. Geertinger P, Sørensen H. Complement as a factor in atherosclerosis. Acta Pathol Microbiol Scand A 1970;78:729-33.
27. Geertinger P, Sørensen H. Complement and arteriosclerosis. Atherosclerosis 1970;18:65-71.
28. Geertinger P, Sørensen H. On the reduced atherogenic effects of cholesterol feeding on rabbits with congenital complement (C6) deficiency. Artery 1977;1:177-84.
29. Hollander W, Colombo MA, Kramsch DM, Kirkpatrick B. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3 complement component, alpha 1 antitrypsin and alpha 2 macroglobulin. Atherosclerosis 1979;34:391-405.
30. Hansson GK, Holm J, Kral IG. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand A 1984;92:429-35.
31. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 1985;55:35-50.
32. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localisation of the terminal C5b-9 complement complex in human aortic fibrous plaques. Atherosclerosis 1985;57:163-7.
33. Rus HG, Niculescu F, Constantinescu E, Cristea A, Vlaicu R. Immunoelectronmicroscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 1986;61:35-42.
34. Niculescu F, Hugo F, Rus HG, Vlaicu R, Bhakdi S. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic plaques. Clin Exp Immunol 1987;69:477-83.
35. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990;172:547-57.
36. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989;9:802-11.
37. Seifert PS, Hansson GK. Decay accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest 1989;84:597-604.
38. Niculescu F, Rus HG, Porutiu D, Ghiurca V, Vlaicu R. Immunoelectron microscopic localization of S protein/vitronectin in human atherosclerotic wall. Atherosclerosis 1989;78:197-203.
39. Seifert PS, Roth I, Schmid W, Oelert H, Okoda N, Okada H, Bhakdi S. CD59, (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack in human atherosclerotic lesions. Atherosclerosis 1992;96:135-45.
40. Hammerschmidt DE, Greenberg CS, Yamada O, Craddock PR, Jakob HS. Cholesterol and atheroma lipids activate complement and stimulate granulocytes: A possible mechanism for amplification of ischemic injury in atherosclerotic state. J Lab Clin Med 1981;98:86-93.
41. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995;238:437-43.
42. Cerilli J, Brasile L, Sosa J, Kremer J, Clarke J, Leather R, Shah D. The role of autoantibody to vascular endothelial cell antigens in atherosclerosis and vascular disease. Transplant Proc 1987;19(4 Suppl 5):47-9.
43. Hansson GK, Lagerstedt E, Bengtsson A, Heideman M. IgG binding to cytoskeletal intermediate filaments activates the complement cascade. Exp Cell Res 1987;170:338-50.
44. Kacharava AG, Tertov W, Orekhov AN. Autoantibodies against low density lipoprotein and atherogenic potential of blood. Ann Med 1993;25:551-5.
45. Stemme S, Hansson GK Immune mechanisms in atherogenesis. Ann Med 1994;26:141-6.
46. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, Rackley CE. Autoantibody titers to oxidized low density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996;131:663-7.
47. Marschang P, Ebenbichler CF, Dierich MP. HIV and complement role of the complement system in HIV infection. Int Arch Allergy Immunol 1994;104:113-7.
48. Melnick JL, Adam E, DeBakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993;14:30-8.
49. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincidences with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989;60:747-57.
50. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, Walev L, Wieland E. On the pathogenesis of atherosclerosis. Enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995;182:1959-71.
51. Kruth HS. Localisation of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin positive oil red O negative particles. Am J Pathol 1984;123:109-25.
52. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu NE. Prelesional events in atherosclerosis: accumulation of extracellular cholesterol rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986;123:109-25.
53. Chao FF, Amenda LM, Blanchette-Mackie EJ, Scarlatos SI, Gamble W, Resau JH, Mergner WT, Kruth HS. Unesterified cholesterol rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol 1988;131:73-83.
54. Frank JS, Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol fed rabbit aortas prepared by ultra rapid freezing and freeze etching. J Lipid Res 1989;30:967-78.
55. Hall RT, Strugnell T, Wu X, Deine DV, Stiver HG. Characterisation of kinetics and target proteins for binding of human complement component C to the surface-exposed outer membrane of Chlamydia trachomatis serovar. Infect Immunol 1993;61:1829-34.
56. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR. Manninen, Manttari M., Frick M.H., Huttunen J.K. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
57. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. J Am Med Assoc 1992;268:68-72.
58. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995;114:165-74.
59. Gerard C, Gerard NP. C5a anaphylatoxin and its seven transmembrane segment receptor. Ann Rev Immunol 1994;12:775-808.
60. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, Haviland JC, Parks WC, Perlmutter DH, Wetzel RA. Cellular Expression of the C5a Anaphylatoxin Receptor (C5aR): Demonstration of C5aR on Nonmyeloid Cells of the Liver and Lung. J Immunol 1995;154:1861-9.
61. Lachmann PJ, Thompson RA. Reactive lysis: The complement mediated lysis of unsensitized cells. II. The characterisation of activated reactor C56 and the participation of C8 and C9. J Exp Med 1970;131:643-57.
62. Pittilo RM, Bull HA, Gulati S, Rowles PM, Blow CM, Machin SJ, Woolf N. Nicotine and cigarette smoking: effects on the ultrastructure of aortic endothelium. Int J Exp Pathol 1990;71:573-86.
63. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990;265:3809-14.
64. Lin PJ, Chang CH, Lee YS, Chou JJ, Chang JP, Hsieh MJ. Acute endothelial reperfusion injury after coronary artery bypass grafting. Ann Thorac Surg 1994;58:782-8.
65. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet derived growth factor from endothelial cells. J Exp Med 1994;179:985-92.
66. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin 8 and monocyte chemoattractant protein 1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996;149:953-61.
67. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP 140 to the cell surface. J Biol Chem 1989;264:9053-60.
68. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor α induced endothelial cell expression of E selectin and ICAM 1. Immunology 1995;155:1434-41.
69. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-13.
70. Leonard EJ, Yoshimura T. Human monocyte chemotactic protein 1 (MCP 1). Immunol Today 1990;11:97-101.
71. Oin S, LaRosa G, Campbell JJ, Smith-Heath H, Kassam N, Shi X, Zeng L, Buthcher EC, Mackay CR. Expression of monocyte chemoattractant protein 1 and interleukin 8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur J Immunol 1996;26:640-7.
72. Bhakdi S. Meeting summary. In: Aggerbeck LP, Angelin B, Bowyer DE, Poledne R, Rosseneu M, Schmitz G, editors. The 14th annual meeting of the European Lipoprotein Club. Arterioscler Thromb 1992;12:536.
73. Waltenberger J, Wanders A, Fellström B, Miyazono K, Heldin C-H, Funa K Induction of transforming growth factor-β during cardiac allograft rejection. J Immunol 1993;151:1147-57.
74. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991;88:904-10.
75. Lovett DH, Haensch GM, Goppelt M, Resch K, Gemsa P. Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol 1987;138:2473-80.
76. Torbohm I, Schönermark M, Winger AM, Berger B, Rother K, Hänsch GM. C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. Kidney Int 1990;37:1098-104.
77. Walport M. Complement. In: Roitt I, Brostoff J, Male D, editors. Immunology, 4th ed. London: Mosby, 1996:1310.